AUROPHARMA

 UPDATE 26-08-18 TIME: 9:30 PM

Aurobindo Pharma

Aurobindo Pharma was founded in 1986 by Mr. P. V. Ramaprasad Reddy and Mr. K. Nityananda Reddy. It started its operation with a single unit manufacturing semi synthetic penicillin (SSPs) at Pondicherry.

It has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

It has set up overseas branches/ representative offices located in Ethiopia, Tanzania, Kenya, Uganda, Italy, Ghana, Vietnam, and United Kingdom.

Aurobindo Pharma has identified international operations, catering to over 100 countries, as a major engine of growth and expanding global network of marketing and manufacturing operations across countries like China, Brazil, Japan, Netherlands, South Africa, Thailand, UK, USA, Russia, Netherlands and many more which will further expand its international reach. Subsidiaries in strategic pharmaceutical markets have positioned it to ride the challenges, powered by the strengths, the brilliance and hard work of its global workforce, stellar track record, ever-growing infrastructure and cost-competitiveness.

Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo’s five units for APIs and four units for formulations are designed for the regulated markets.

Its manufacturing units is approved by USFDA, UKMHRA, WHO, MCC-SA and ANVISA-Brazil

In 2012 Aurobindo Pharma commenced business journey into peptides segment. Aurobindo Pharma Ltd. launched its operations in the Kingdom of Bahrain through a grand event held at Hotel Radisson Blu on Monday, 17th Sep’2012.

In April 2014 Aurobindo Pharma Limited announced the completion of the previously announced acquisition of certain commercial operations in Western Europe from Actavis plc (NYSE: ACT). The agreement to acquire the Actavis operations was announced in January 2014.

 

Performance Today : Outperformed Sector by 1.15%

Consecutive Rise: Stock has been gaining for the last 9 days and has risen 15.38% in the period

Moving Averages: Stock has traded higher than 5 day, 20 day, 50 day, 100 day and 200 day moving average.

Falling Investor Participation: Delivery Vol of 9.75 lacs on 24 Aug has fallen by -31.79% against 5-day avg delivery vol

Liquidity: Based on 2% of 5 day average traded Value the stock is liquid enough for trade size of Rs 6.18 cr

Industry Pharma

Market cap Rs 36,186 Cr (Large Cap) — P/E 15.33

Industry P/E 26.63 / Dividend Yield 0.40 % / Debt Equity 0.28 Return on Equity 20.75 % / Price to Book 3.10

Net Sales Rs 4,181.56 cr Net Profit (Quarterly Results – Jun 2018)  Rs 455.66 Cr

Standalone Quarterly Results

Total Operating income Jun 2018

2,558.82

Mar 2018

2,354.72

8.67%
Net Sales 2,491.62 2,296.32 8.50%
Other Operating Income 67.20 58.40 15.07%
Total Expenditure (Excl Depreciation) 2,162.06 1,876.84 15.20%
Raw Material Cost 1,433.97 1,191.49 20.35%
Purchase of Finished goods 2.53 0.42 502.38%
(Increase) / Decrease In Stocks -119.13 -90.49 -31.65%
Employee Cost 319.29 317.39 0.60%
Power Cost 0.00 0.00
Manufacturing Expenses 475.44 458.03 3.80%
Selling and Distribution Expenses 0.00 0.00
Other Expenses 49.96 0.00
Operating Profit (PBDIT) excl Other Income 396.76 477.88 -16.97%
Other Income 2.82 6.36 -55.66%
Operating Profit (PBDIT) 399.58 484.24 -17.48%
Interest 23.87 17.41 37.11%
Exceptional Items 0.00 0.00
Gross Profit (PBDT) 375.71 466.83 -19.52%
Depreciation 93.66 91.55 2.30%
Profit Before Tax 282.05 375.28 -24.84%
Tax 56.93 66.99 -15.02%
Provisions and contingencies 0.00 0.00
Profit After Tax 225.12 308.29 -26.98%
Extraordinary Items 0.00 0.00
Prior Period Expenses 0.00 0.00
Other Adjustments 0.00 0.00
Net Profit 225.12 308.29 -26.98%
Equity Capital 58.59 58.59
Face Value (IN RS) 1.00 1.00
Reserves 0.00 0.00
Earnings per share (EPS) 3.84 5.26 -26.98%
Diluted Earnings per share 3.84 5.26 -27.00%
Operating Profit Margin (Excl OI) 15.51% 20.29% -4.79%
Gross Profit Margin 14.68% 19.83% -5.14%
PAT Margin 8.80% 13.09% -4.29%
Public Share Holdings (%) 0.00% 0.00%
Pledged Promotor Holding (%) 0.00% 0.00%

 

Share Holding Pattern

AUROPHARMA
AUROPHARMA